Secondary mutation in a coding mononucleotide tract in MSH6 causes loss of immunoexpression of MSH6 in colorectal carcinomas with MLH1/PMS2 deficiency

Modern Pathology

Volumn 26, Issue 1, 2013, Pages 131-138

  Shia, Jinru ^a   Zhang, Liying ^a   Shike, Moshe ^a   Guo, Min ^a   Stadler, Zsofia ^a   Xiong, Xiaoling ^a   Tang, Laura H ^a   Vakiani, Efsevia ^a   Katabi, Nora ^a   Wang, Hangjun ^a   Bacares, Ruben ^a   Ruggeri, Jeanine ^a   Boland, C Richard ^b   Ladanyi, Marc ^a   Klimstra, David S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

DNA mismatch repair; hereditary non polyposis colorectal carcinoma; immunohistochemistry; Lynch syndrome; microsatellite instability

Indexed keywords

DNA; MICROSATELLITE DNA; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH6;

ADULT; AGED; ARTICLE; BASE MISPAIRING; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CHEMORADIOTHERAPY; CLINICAL EVALUATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DNA DETERMINATION; EXON; FEMALE; FRAMESHIFT MUTATION; GENE MUTATION; GENETIC CODE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; STAINING; TUMOR CELL;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEAR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; YOUNG ADULT;

EID: 84871918963     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.138     Document Type: Article

References (17)

1. Shia J. Immunohistochemistry versus microsatelliteinstability testing for screening colorectal cancerpatients at risk for hereditary nonpolyposis colorectalcancer syndrome. Part I. The utility of immunohistochemistry.J Mol Diagn 2008;10:293-300. (Pubitemid 352019113)
2. Boland CR, Shike M. Report from the Jerusalemworkshop on Lynch syndrome-hereditary nonpolyposiscolorectal cancer. Gastroenterology 2010;138:e1-e7.
3. Zhang L. Immunohistochemistry versus microsatelliteinstability testing for screening colorectal cancerpatients at risk for hereditary nonpolyposis colorectalcancer syndrome. Part II. The utility of microsatelliteinstability testing. J Mol Diagn 2008;10:301-307. (Pubitemid 352019114)
4. Boland CR, Koi M, Chang DK, et al. The biochemicalbasis of microsatellite instability and abnormal immunohistochemistryand clinical behavior in Lynchsyndrome: from bench to bedside. Fam Cancer 2008;7:41-52.
5. Umar A, Boland CR, Terdiman JP, et al. RevisedBethesda Guidelines for hereditary nonpolyposis colorectalcancer (Lynch syndrome) and microsatelliteinstability. J Natl Cancer Inst 2004;96:261-268.
6. Radu OM, Nikiforova MN, Farkas LM, et al. Challengingcases encountered in colorectal cancer screeningfor Lynch syndrome reveal novel findings: nucleolarMSH6 staining and impact of prior chemoradiationtherapy. Hum Pathol 2011;42:1247-1258.
7. Bao F, Panarelli NC, Rennert H, et al. Neoadjuvanttherapy induces loss of MSH6 expression in colorectalcarcinoma. Am J Surg Pathol 2010;34:1798-1804.
8. Pinol V, Castells A, Andreu M, et al. Accuracy ofrevised Bethesda guidelines, microsatellite instability,and immunohistochemistry for the identification ofpatients with hereditary nonpolyposis colorectal cancer.J Am Med Assoc 2005;293:1986-1994. (Pubitemid 40570892)
9. Malkhosyan S, Rampino N, Yamamoto H, et al. Frameshiftmutator mutations. Nature 1996;382:499-500.
10. Gifford G, Paul J, Vasey PA, et al. The acquisition ofhMLH1 methylation in plasma DNA after chemotherapypredicts poor survival for ovarian cancer patients.Clin Cancer Res 2004;10:4420-4426. (Pubitemid 38878884)
11. Ohmiya N, Matsumoto S, Yamamoto H, et al. Germlineand somatic mutations in hMSH6 and hMSH3 ingastrointestinal cancers of the microsatellite mutatorphenotype. Gene 2001;272:301-313. (Pubitemid 32695423)
12. Hunter C, Smith R, Cahill DP, et al. A hypermutationphenotype and somatic MSH6 mutations in recurrenthuman malignant gliomas after alkylator chemotherapy.Cancer Res 2006;66:3987-3991.
13. Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise inglioblastomas during temozolomide therapy and mediatetemozolomide resistance. Clin Cancer Res 2009;15:4622-4629.
14. Chang CL, Marra G, Chauhan DP, et al. Oxidative stressinactivates the human DNA mismatch repair system.Am J Physiol Cell Physiol 2002;283:C148-C154. (Pubitemid 34670558)
15. Bindra RS, Crosby ME, Glazer PM. Regulation of DNArepair in hypoxic cancer cells. Cancer Metastasis Rev2007;26:249-260. (Pubitemid 47101664)
16. Rodriguez-Jimenez FJ, Moreno-Manzano V, Lucas-Dominguez R, et al. Hypoxia causes downregulationof mismatch repair system and genomic instability instem cells. Stem Cells 2008;26:2052-2062.
17. Mihaylova VT, Bindra RS, Yuan J, et al. Decreasedexpression of the DNA mismatch repair gene Mlh1under hypoxic stress in mammalian cells. Mol CellBiol 2003;23:3265-3273. (Pubitemid 36459239)